Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
57.22
+1.60 (2.88%)
Sep 16, 2025, 10:52 AM EDT - Market open
Novo Nordisk Employees
As of December 31, 2024, Novo Nordisk had 77,349 total employees, including 76,302 full-time and 1,047 part-time employees. The number of employees increased by 13,030 or 20.26% compared to the previous year.
Employees
77,349
Change (1Y)
13,030
Growth (1Y)
20.26%
Revenue / Employee
$634,901
Profits / Employee
$226,061
Market Cap
248.69B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
Dec 31, 2020 | 45,323 | 2,065 | 4.77% |
Dec 31, 2019 | 43,258 | 56 | 0.13% |
Dec 31, 2018 | 43,202 | 520 | 1.22% |
Dec 31, 2017 | 42,682 | 711 | 1.69% |
Dec 31, 2016 | 41,971 | 1,333 | 3.28% |
Dec 31, 2015 | 40,638 | -319 | -0.78% |
Dec 31, 2014 | 40,957 | 2,521 | 6.56% |
Dec 31, 2013 | 38,436 | 3,705 | 10.67% |
Dec 31, 2012 | 34,731 | 2,099 | 6.43% |
Dec 31, 2011 | 32,632 | 2,149 | 7.05% |
Dec 31, 2010 | 30,483 | 1,154 | 3.93% |
Dec 31, 2009 | 29,329 | 2,754 | 10.36% |
Dec 31, 2008 | 26,575 | 1,059 | 4.15% |
Dec 31, 2007 | 25,516 | 1,903 | 8.06% |
Dec 31, 2006 | 23,613 | 1,153 | 5.13% |
Dec 31, 2005 | 22,460 | 1,735 | 8.37% |
Dec 31, 2004 | 20,725 | 1,969 | 10.50% |
Dec 31, 2003 | 18,756 | 751 | 4.17% |
Dec 31, 2002 | 18,005 | 1,864 | 11.55% |
Dec 31, 2001 | 16,141 | 2,389 | 17.37% |
Dec 31, 2000 | 13,752 | 1,758 | 14.66% |
Dec 31, 1999 | 11,994 | 345 | 2.96% |
Dec 31, 1998 | 11,649 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
NVO News
- 3 hours ago - Novo Nordisk to test weight-loss drugs in broader range of obesity-linked conditions - Reuters
- 3 hours ago - Novo Nordisk flags drug trial promise amid hunt for next weight-loss blockbuster - CNBC
- 4 hours ago - Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme - GlobeNewsWire
- 7 hours ago - Novo Nordisk's Wegovy Helps Suppress Thoughts About Food, Study Suggests - WSJ
- 15 hours ago - The Secret Blue-Chip Rally No One Knows About: 4 Amazing Ideas To Consider - Seeking Alpha
- 22 hours ago - Novo Nordisk: The Market Is Giving Us A Free Lunch - Seeking Alpha
- 1 day ago - Novo Nordisk Stock Rises. Its Diabetes Pill Cleared a Key Hurdle. - Barrons
- 1 day ago - Novo Nordisk's Diabetes Pill Gets EU Label Extension For Heart Benefits - WSJ